Efficacy and Safety of Tirzepatide in Type 2 Diabetes and Obesity Management

Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes

(2022) Dominik Dahl et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

338-OR: Tirzepatide Reduces Appetite, Energy Intake, and Fat Mass in People with T2D

(2022) TIM HEISE et al.   DIABETES

Efficacy of tirzepatide 5, 10, and 15 mg versus semaglutide 2 mg in patients with type 2 diabetes: an adjusted indirect treatment comparison

(2022) Karan Vadher et al.   DIABETES OBESITY & METABOLISM

Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis

(2022) Naveed Sattar et al.   NATURE MEDICINE

Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial

(2022) Tim Heise et al.   Lancet Diabetes & Endocrinology

Efficacy of once-weekly tirzepatide versus once-daily insulin degludec on glycaemic control measured by continuous glucose monitoring in adults with type 2 diabetes (SURPASS-3 CGM): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial

(2022) Tadej Battelino et al.   Lancet Diabetes & Endocrinology

Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial

(2022) Amalia Gastaldelli et al.   Lancet Diabetes & Endocrinology

Tirzepatide for the treatment of adults with type 2 diabetes: an endocrine perspective

(2022) Christophe De Block et al.   DIABETES OBESITY & METABOLISM

Tirzepatide: First Approval

(2022) Yahiya Y. Syed   DRUGS

Tirzepatide Once Weekly for the Treatment of Obesity

(2022) Ania M. Jastreboff et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy and safety of tirzepatide monotherapy compared with dulaglutide in Japanese patients with type 2 diabetes (SURPASS J-mono): a double-blind, multicentre, randomised, phase 3 trial

(2022) Nobuya Inagaki et al.   Lancet Diabetes & Endocrinology

Safety and efficacy of tirzepatide as an add-on to single oral antihyperglycaemic medication in patients with type 2 diabetes in Japan (SURPASS J-combo): a multicentre, randomised, open-label, parallel-group, phase 3 trial

(2022) Takashi Kadowaki et al.   Lancet Diabetes & Endocrinology

Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction

(2022) Michael A. Nauck et al.   Cardiovascular Diabetology

Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

(2022) Melanie J. Davies et al.   DIABETOLOGIA

LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial

(2022) Shweta Urva et al.   LANCET

Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS-4 trial: post-hoc analysis of an open-label, randomised, phase 3 trial

(2022) Hiddo J L Heerspink et al.   Lancet Diabetes & Endocrinology

New therapies for obesity

(2022) Dimitris Papamargaritis et al.   CARDIOVASCULAR RESEARCH

BI 456906: Discovery and preclinical pharmacology of a novel GCGR/GLP-1R dual agonist with robust anti-obesity efficacy

(2022) Tina Zimmermann et al.   Molecular Metabolism

The glucose-dependent insulinotropic polypeptide (GIP) regulates body weight and food intake via CNS-GIPR signaling

(2021) Qian Zhang et al.   Cell Metabolism

Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity

(2021) Thomas A. Wadden et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial

(2021) Melanie Davies et al.   LANCET

Once-Weekly Semaglutide in Adults with Overweight or Obesity

(2021) John P.H. Wilding et al.   NEW ENGLAND JOURNAL OF MEDICINE

Effects of Renal Impairment on the Pharmacokinetics of the Dual GIP and GLP-1 Receptor Agonist Tirzepatide

(2021) Shweta Urva et al.   CLINICAL PHARMACOKINETICS

Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity

(2021) Domenica Rubino et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg for weight management: a randomised, controlled, phase 1b trial

(2021) Lone B Enebo et al.   LANCET

Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial

(2021) Julio Rosenstock et al.   LANCET

Tirzepatide and the new era of twincretins for diabetes

(2021) Tricia M-M Tan et al.   LANCET

Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial

(2021) Bernhard Ludvik et al.   LANCET

Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes

(2021) Juan P. Frías et al.   NEW ENGLAND JOURNAL OF MEDICINE

Effects on weight loss and glycemic control with SAR441255, a potent unimolecular peptide GLP-1/GIP/GCG receptor triagonist

(2021) Martin Bossart et al.   Cell Metabolism

A phase 1 multiple‐ascending dose study of tirzepatide in Japanese participants with type 2 diabetes

(2021) Kenichi Furihata et al.   DIABETES OBESITY & METABOLISM

Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial

(2021) Stefano Del Prato et al.   LANCET

Obesity management as a primary treatment goal for type 2 diabetes: time to reframe the conversation

(2021) Ildiko Lingvay et al.   LANCET

Anti-obesity drug discovery: advances and challenges

(2021) Timo D. Müller et al.   NATURE REVIEWS DRUG DISCOVERY

Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials

(2021) Naveed Sattar et al.   Lancet Diabetes & Endocrinology

Amylin as a Future Obesity Treatment

(2021) Babak Dehestani et al.   Journal of Obesity & Metabolic Syndrome

No Acute Effects of Exogenous Glucose-Dependent Insulinotropic Polypeptide on Energy Intake, Appetite, or Energy Expenditure When Added to Treatment With a Long-Acting Glucagon-Like Peptide 1 Receptor Agonist in Men With Type 2 Diabetes

(2020) Natasha C. Bergmann et al.   DIABETES CARE

Efficacy and Safety of Liraglutide 3.0 mg in Individuals With Overweight or Obesity and Type 2 Diabetes Treated With Basal Insulin: The SCALE Insulin Randomized Controlled Trial

(2020) W. Timothy Garvey et al.   DIABETES CARE

Efficacy and tolerability of tirzepatide, a dual glucose‐dependent insulinotropic peptide and glucagon‐like peptide‐1 receptor agonist in patients with type 2 diabetes: A 12‐week, randomized, double‐blind, placebo‐controlled study to evaluate different dose‐escalation regimens

(2020) Juan Pablo Frias et al.   DIABETES OBESITY & METABOLISM

GIP as a therapeutic target in diabetes and obesity: insight from incretin co-agonists

(2020) Jens Juul Holst et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Combination gut hormones: prospects and questions for the future of obesity and diabetes therapy

(2020) Bernard Khoo et al.   JOURNAL OF ENDOCRINOLOGY

The novel dual glucose‐dependent insulinotropic polypeptide and glucagon‐like peptide‐1 ( GLP ‐1) receptor agonist tirzepatide transiently delays gastric emptying similarly to selective long‐acting GLP ‐1 receptor agonists

(2020) Shweta Urva et al.   DIABETES OBESITY & METABOLISM

How May GIP Enhance the Therapeutic Efficacy of GLP-1?

(2020) Ricardo J. Samms et al.   TRENDS IN ENDOCRINOLOGY AND METABOLISM

Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist

(2020) Francis S. Willard et al.   JCI Insight

Glucagon-like peptide-1 receptor co-agonists for treating metabolic disease

(2020) Laurie L. Baggio et al.   Molecular Metabolism

The Role of Tirzepatide, Dual GIP and GLP-1 Receptor Agonist, in the Management of Type 2 Diabetes: The SURPASS Clinical Trials

(2020) Thinzar Min et al.   Diabetes Therapy

Durability of a primary care-led weight-management intervention for remission of type 2 diabetes: 2-year results of the DiRECT open-label, cluster-randomised trial

(2019) Michael E J Lean et al.   Lancet Diabetes & Endocrinology

Effects of combined GIP and GLP-1 infusion on energy intake, appetite and energy expenditure in overweight/obese individuals: a randomised, crossover study

(2019) Natasha C. Bergmann et al.   DIABETOLOGIA

Glucagon-like peptide 1 (GLP-1)

(2019) T.D. Müller et al.   Molecular Metabolism

Efficacy, safety, and mechanistic insights of cotadutide a dual receptor glucagon-like peptide-1 and glucagon agonist

(2019) Victoria E R Parker et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

GIP’s involvement in the pathophysiology of type 2 diabetes

(2019) Mikkel B. Christensen et al.   PEPTIDES

Achievement of guideline targets for blood pressure, lipid, and glycaemic control in type 2 diabetes: A meta-analysis

(2018) Kamlesh Khunti et al.   DIABETES RESEARCH AND CLINICAL PRACTICE

Maintenance of Lost Weight and Long-Term Management of Obesity

(2018) Kevin D. Hall et al.   MEDICAL CLINICS OF NORTH AMERICA

Comparative Effectiveness and Safety of Bariatric Procedures for Weight Loss

(2018) David Arterburn et al.   ANNALS OF INTERNAL MEDICINE

Cracking the combination: Gut hormones for the treatment of obesity and diabetes

(2018) Kleopatra Alexiadou et al.   JOURNAL OF NEUROENDOCRINOLOGY

Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial

(2018) Juan Pablo Frias et al.   LANCET

LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept

(2018) Tamer Coskun et al.   Molecular Metabolism

Glucose-Dependent Insulinotropic Polypeptide (GIP) Inhibits Bone Resorption Independently of Insulin and Glycemia

(2017) Mikkel B Christensen et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Obesity and Type 2 Diabetes: Two Diseases with a Need for Combined Treatment Strategies - EASO Can Lead the Way

(2017) Deborah R. Leitner et al.   Obesity Facts

Occurrence of nausea, vomiting and diarrhoea reported as adverse events in clinical trials studying glucagon-like peptide-1 receptor agonists: A systematic analysis of published clinical trials

(2016) Karolin Bettge et al.   DIABETES OBESITY & METABOLISM

Trends in adult body-mass index in 200 countries from 1975 to 2014: a pooled analysis of 1698 population-based measurement studies with 19·2 million participants

(2016)   LANCET

Association of the magnitude of weight loss and changes in physical fitness with long-term cardiovascular disease outcomes in overweight or obese people with type 2 diabetes: a post-hoc analysis of the Look AHEAD randomised clinical trial

(2016)   Lancet Diabetes & Endocrinology

The incretin effect in healthy individuals and those with type 2 diabetes: physiology, pathophysiology, and response to therapeutic interventions

(2016) Michael A Nauck et al.   Lancet Diabetes & Endocrinology

Advances in the Science, Treatment, and Prevention of the Disease of Obesity: Reflections From aDiabetes CareEditors’ Expert Forum

(2015) William T. Cefalu et al.   DIABETES CARE

Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes

(2015) Melanie J. Davies et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management

(2015) Xavier Pi-Sunyer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Association of Bariatric Surgery With Long-term Remission of Type 2 Diabetes and With Microvascular and Macrovascular Complications

(2014) Lars Sjöström et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Can medical therapy mimic the clinical efficacy or physiological effects of bariatric surgery?

(2013) A D Miras et al.   INTERNATIONAL JOURNAL OF OBESITY

Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: The SCALE Maintenance randomized study

(2013) T A Wadden et al.   INTERNATIONAL JOURNAL OF OBESITY

Review of the key results from the Swedish Obese Subjects (SOS) trial - a prospective controlled intervention study of bariatric surgery

(2013) L. Sjöström   JOURNAL OF INTERNAL MEDICINE

Cardiovascular Effects of Intensive Lifestyle Intervention in Type 2 Diabetes

(2013)   NEW ENGLAND JOURNAL OF MEDICINE

Eight-year weight losses with an intensive lifestyle intervention: The look AHEAD study

(2013)   Obesity

Obesity: The Gateway to Ill Health - an EASO Position Statement on a Rising Public Health, Clinical and Scientific Challenge in Europe

(2013) Gema Frühbeck et al.   Obesity Facts

Interdisciplinary European Guidelines on Metabolic and Bariatric Surgery

(2013) M. Fried et al.   OBESITY SURGERY

Unimolecular Dual Incretins Maximize Metabolic Benefits in Rodents, Monkeys, and Humans

(2013) B. Finan et al.   Science Translational Medicine

The separate and combined impact of the intestinal hormones, GIP, GLP-1, and GLP-2, on glucagon secretion in type 2 diabetes

(2011) Asger Lund et al.   AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM

Administration of an acylated GLP-1 and GIP preparation provides added beneficial glucose-lowering and insulinotropic actions over single incretins in mice with Type 2 diabetes and obesity

(2011) Victor A. Gault et al.   CLINICAL SCIENCE

The metabolic actions of glucagon revisited

(2010) Kirk M. Habegger et al.   Nature Reviews Endocrinology

Four weeks of near-normalisation of blood glucose improves the insulin response to glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes

(2008) P. V. Højberg et al.   DIABETOLOGIA